590 related articles for article (PubMed ID: 31194225)
1. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Vinayak S; Tolaney SM; Schwartzberg L; Mita M; McCann G; Tan AR; Wahner-Hendrickson AE; Forero A; Anders C; Wulf GM; Dillon P; Lynce F; Zarwan C; Erban JK; Zhou Y; Buerstatte N; Graham JR; Arora S; Dezube BJ; Telli ML
JAMA Oncol; 2019 Aug; 5(8):1132-1140. PubMed ID: 31194225
[TBL] [Abstract][Full Text] [Related]
2. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos PA; Waggoner S; Vidal GA; Mita M; Moroney JW; Holloway R; Van Le L; Sachdev JC; Chapman-Davis E; Colon-Otero G; Penson RT; Matulonis UA; Kim YB; Moore KN; Swisher EM; Färkkilä A; D'Andrea A; Stringer-Reasor E; Wang J; Buerstatte N; Arora S; Graham JR; Bobilev D; Dezube BJ; Munster P
JAMA Oncol; 2019 Aug; 5(8):1141-1149. PubMed ID: 31194228
[TBL] [Abstract][Full Text] [Related]
3. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N; Tang Y; Teslenko I; Iannotti N
Cancer; 2022 Jan; 128(1):65-74. PubMed ID: 34478166
[TBL] [Abstract][Full Text] [Related]
4. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
[TBL] [Abstract][Full Text] [Related]
5. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
9. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Gillece JD; Folkerts M; Reining L; Highlander SK; Robinson K; Padam S; Martinez N; Tang A; Schmolze D; Waisman J; Sedrak M; Lee PP; Mortimer J
Oncologist; 2021 Feb; 26(2):99-e217. PubMed ID: 33141975
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
14. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial.
Jameson GS; Borazanci E; Babiker HM; Poplin E; Niewiarowska AA; Gordon MS; Barrett MT; Rosenthal A; Stoll-D'Astice A; Crowley J; Shemanski L; Korn RL; Ansaldo K; Lebron L; Ramanathan RK; Von Hoff DD
JAMA Oncol; 2020 Jan; 6(1):125-132. PubMed ID: 31580386
[TBL] [Abstract][Full Text] [Related]
15. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
Ho AY; Barker CA; Arnold BB; Powell SN; Hu ZI; Gucalp A; Lebron-Zapata L; Wen HY; Kallman C; D'Agnolo A; Zhang Z; Flynn J; Dunn SA; McArthur HL
Cancer; 2020 Feb; 126(4):850-860. PubMed ID: 31747077
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Kessler ER; Callihan E; Hu J; Eule C; Srivastava G; Kemme DJ; Iruku P; Rana V; Moore J; Schuster SR; Amirault M; Flaig TW; Lam ET
Cancer Res Commun; 2023 Jun; 3(6):1004-1012. PubMed ID: 37377613
[TBL] [Abstract][Full Text] [Related]
18. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
20. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Arance A; de la Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Márquez-Rodas I; Spreafico A; Atkinson V; Costa Svedman F; Mant A; Khattak MA; Mihalcioiu C; Jang S; Cowey CL; Smith AD; Hawk N; Chen K; Diede SJ; Krepler C; Long GV
J Clin Oncol; 2023 Jan; 41(1):75-85. PubMed ID: 35867951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
